INVANZ Drug Patent Profile

✉ Email this page to a colleague

When do Invanz patents expire, and when can generic versions of Invanz launch?

Invanz is a drug marketed by Msd Sub Merck and is included in one NDA.

The generic ingredient in INVANZ is ertapenem sodium. There are eight drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the ertapenem sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Invanz

A generic version of INVANZ was approved as ertapenem sodium by ACS DOBFAR SPA on April 16^th, 2018.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for INVANZ?
What are the global sales for INVANZ?
What is Average Wholesale Price for INVANZ?

Summary for INVANZ

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	58
Clinical Trials:	21
Patent Applications:	4,204
Drug Prices:	Drug price information for INVANZ
What excipients (inactive ingredients) are in INVANZ?	INVANZ excipients list
DailyMed Link:	INVANZ at DailyMed

Drug patent expirations by year for INVANZ

Recent Clinical Trials for INVANZ

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Todd C. Lee MD MPH FIDSA	Phase 2
Iterum Therapeutics, US Limited	Phase 3
Iterum Therapeutics, International Limited	Phase 3

See all INVANZ clinical trials

Pharmacology for INVANZ

Drug Class	Penem Antibacterial

Paragraph IV (Patent) Challenges for INVANZ

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INVANZ	Injection	ertapenem sodium	1 g/vial	021337	1	2012-12-21

US Patents and Regulatory Information for INVANZ

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd Sub Merck	INVANZ	ertapenem sodium	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS	021337-001	Nov 21, 2001	AP	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for INVANZ

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Msd Sub Merck	INVANZ	ertapenem sodium	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS	021337-001	Nov 21, 2001	⤷ Sign Up	⤷ Sign Up
Msd Sub Merck	INVANZ	ertapenem sodium	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS	021337-001	Nov 21, 2001	⤷ Sign Up	⤷ Sign Up
Msd Sub Merck	INVANZ	ertapenem sodium	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS	021337-001	Nov 21, 2001	⤷ Sign Up	⤷ Sign Up
Msd Sub Merck	INVANZ	ertapenem sodium	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS	021337-001	Nov 21, 2001	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for INVANZ

See the table below for patents covering INVANZ around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Hungary	9901567		⤷ Sign Up
Czech Republic	9302067		⤷ Sign Up
South Korea	100200986		⤷ Sign Up
Ukraine	62920	CARBAPENEME ANTIBIOTIC, A COMPOSITION AND A METHOD FOR THE PREPARATION	⤷ Sign Up
Portugal	863901		⤷ Sign Up
Germany	69725696		⤷ Sign Up
Austria	252584		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for INVANZ

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0579826	10299041	Germany	⤷ Sign Up	PRODUCT NAME: ERTAPENEM UND PHARMAZEUTISCH VERTRAEGLICHE SALZE HIERVON, EINSCHLIESSLICH ERTAPENEM-NATRIUM; REGISTRATION NO/DATE: EU/1/02/216/001 20020418
0579826	SPC/GB02/042	United Kingdom	⤷ Sign Up	PRODUCT NAME: ERTAPENEM ((1R,5S,6S,8R,2'S,4'S)-2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)-6-(1-HYDROXYETHYL)-1-METHYLCARBAPENEM-3-CARBOXYLIC ACID), A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF, ESPECIALLY AS THE MONOSODIUM SALT ERTA; REGISTERED: UK EU/1/02/216/001 20020422
0579826	300104	Netherlands	⤷ Sign Up	PRODUCT NAME: ERTAPENEM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ERTAPENEMNATRIUM; REGISTRATION NO/DATE: EU/1/02/216/001 20020422
0579826	02C0041	France	⤷ Sign Up	PRODUCT NAME: ERTAPENEM SODIUM; REGISTRATION NO/DATE: EU/1/02/216/001 20020418
0863901	PA2004008,C0863901	Lithuania	⤷ Sign Up	PRODUCT NAME: ERTAPENEMUM ((4R,5S,6S)-3-((3S,5S)-5-((3-KARBOKSIFENIL)AMINO)KARBONIL)-3-PIROLIDINIL)TIO)-6-((1R)-1HIDROKSIETIL)-4-METIL-7-OKSO-1-AZABICIKLO-(3.2.0)HEPT-2-EN-2-KARBOKSIRUGSTIS; REGISTRATION NO/DATE: 03/8043/3 20030328
0579826	CA 2002 00025	Denmark	⤷ Sign Up	PRODUCT NAME: ERTAPENEM OG FARMACEUTISK ACCEPTABLE SALTE DERAF
0579826	36/2002	Austria	⤷ Sign Up	PRODUCT NAME: ERTAPENEM UND ALLE PHARMAZEUTISCH ANNEHMBAREN SALZE DAVON, INSBESONDERE NATRIUM-ERTAPENEM; REGISTRATION NO/DATE: EU/1/02/216/001 20020418
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description